Lilly Affirms Immunology Interest with US$605 M ImmuNext Deal
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 4 (Table of Contents)
Published: 2 Apr-2019
DOI: 10.3833/pdr.v2019.i4.2414 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In another sign of its commitment to immunology, Eli Lilly has entered into a licensing and research collaboration with ImmuNext to develop immunometabolism therapies for the treatment of autoimmune diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS